Gerd Lärfars

Subcutaneous Adjusted-Dose Unfractionated Heparin vs Fixed-Dose Low-Molecular-Weight Heparin in the Initial Treatment of Venous Thromboembolism

6 versus 30 months anticoagulation for recurrent venous thrombosis in patients with high factor VIII

Major bleeding during secondary prevention of venous thromboembolism in patients who have completed anticoagulation: a systematic review and meta‐analysis

Use of Epoetin and Darbepoetin in Patients With Cancer: 2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update

Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism

Microenvironmental modulation breaks intrinsic pH limitations of nanozymes to boost their activities

Aspirin for Preventing the Recurrence of Venous Thromboembolism

A Population-Based Study of the Effectiveness of Inferior Vena Cava Filter Use Among Patients With Venous Thromboembolism

Diagnosis and management of anaemia of chronic disease: current status

Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT)

Individually tailored duration of elastic compression therapy in relation to incidence of the postthrombotic syndrome

A conceptual framework for two phases of anticoagulant treatment of venous thromboembolism

Hypersensitivity from Intravenous Iron Products

Antithrombotic Therapy for Venous Thromboembolic Disease

Pulmonary Embolism

Incidence of Cancer after Prophylaxis with Warfarin against Recurrent Venous Thromboembolism

Low-Molecular-Weight Heparin: The Optimal Duration of Prophylaxis Against Postoperative Venous Thromboembolism After Total Hip or Knee Replacement

Phlebotomies or erythropoietin injections allow mobilization of iron stores in a mouse model mimicking intensive care anemia

Isolated calf deep vein thrombosis in the community setting: the Worcester Venous Thromboembolism study

Echocardiography Doppler in pulmonary embolism: Right ventricular dysfunction as a predictor of mortality rate

A Clinical Trial of Vena Caval Filters in the Prevention of Pulmonary Embolism in Patients with Proximal Deep-Vein Thrombosis

Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism

The Risk of Recurrent Venous Thromboembolism in Patients with an Arg⁵⁰⁶→Gln Mutation in the Gene for Factor V (Factor V Leiden)

Intracerebral haemorrhage

Recurrent Venous Thromboembolism After Deep Vein Thrombosis

Venous thromboembolism: disease burden, outcomes and risk factors

Chronic Venous Disease

The controversy of managing calf vein thrombosis

Prognosis of Cancers Associated with Venous Thromboembolism

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

Predictors of Recurrence After Deep Vein Thrombosis and Pulmonary Embolism

Risk of Recurrent Venous Thromboembolism in Patients With Common Thrombophilia

Risk of Recurrence After a First Episode of Symptomatic Venous Thromboembolism Provoked by a Transient Risk Factor

Antithrombotic Therapy for VTE Disease

Intracranial and fatal bleeding according to indication for long‐term oral anticoagulant therapy

The role of vena caval filters in the management of venous thromboembolism

Targeting the hepcidin–ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation

Validation of Clinical Classification Schemes for Predicting Stroke

Prognostic Value of ECG Among Patients with Acute Pulmonary Embolism and Normal Blood Pressure

Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism

Unresolved issues in anticoagulant therapy

High Plasma Levels of Factor VIII and the Risk of Recurrent Venous Thromboembolism

G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism

Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy

Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER)

Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient‐level meta‐analysis

Deep-vein thrombosis

Treatment of Deep-Vein Thrombosis

Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis

Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention

Duration of Venous Thromboembolism Prophylaxis After Surgery

Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism

Antithrombotic Therapy for VTE Disease

Incidence of Chronic Thromboembolic Pulmonary Hypertension after Pulmonary Embolism

Deep Venous Thrombosis

Platelet Activation and Atherothrombosis

Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism

Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials

d -Dimer Testing to Determine the Duration of Anticoagulation Therapy

The risk of recurrent venous thromboembolism: The Austrian Study on Recurrent Venous Thromboembolism

The Antiphospholipid Syndrome

Symptomatic Pulmonary Embolism and the Risk of Recurrent Venous Thromboembolism

Cerebral Sinovenous Thrombosis in Children

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

Oral Anticoagulants

Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study

Prevention of Venous Thromboembolism

D-dimer levels in combination with residual venous obstruction and the risk of recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis

Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer

D‐dimer at venous thrombosis diagnosis is associated with risk of recurrence

Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range

D-Dimer Levels and Risk of Recurrent Venous Thromboembolism

Pulmonary thromboembolic disease spectrum: diagnostic and therapeutic strategies

Safety of Treatment with Oral Anticoagulants in the Elderly

Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty

Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial

The Incidence of Recurrent Venous Thromboembolism After Treatment With Vitamin K Antagonists in Relation to Time Since First Event

Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis

Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: Reference patterns for age‐related changes and disease‐induced shifts

Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study

The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment

Prevention of Venous Thromboembolism

Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism

The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients

Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran

Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis

Anticardiolipin Antibodies Predict Early Recurrence of Thromboembolism and Death Among Patients with Venous Thromboembolism Following Anticoagulant Therapy

The post-thrombotic syndrome: current knowledge, controversies, and directions for future research

Antithrombotic Therapy for Venous Thromboembolic Disease

The Risk of Recurrent Venous Thromboembolism in Men and Women

Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment

Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial

Ultrasound-accelerated Thrombolysis for the Treatment of Deep Vein Thrombosis: Initial Clinical Experience

Deep-Vein Thrombosis of the Upper Extremities

Measuring the Outcomes and Pharmacoeconomic Consequences of Venous Thromboembolism Prophylaxis in Major Orthopaedic Surgery

Deep vein thrombosis

Hemorrhagic Complications of Anticoagulant Treatment

Cost-effective Prevention of Pulmonary Embolus in High-risk Trauma Patients

A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients

Risk of Fatal Pulmonary Embolism in Patients With Treated Venous Thromboembolism

Hemorrhagic Complications of Anticoagulant Treatment

Rates of Initial and Recurrent Thromboembolic Disease Among Patients with Malignancy Versus Those without Malignancy: Risk Analysis Using Medicare Claims Data

Prevention of Venous Thromboembolism

Hemorrhagic Complications of Anticoagulant Treatment

Oral Apixaban for the Treatment of Acute Venous Thromboembolism

Management of Venous Thromboembolism

Antithrombotic Therapy for Venous Thromboembolic Disease

Thrombosis of the Cerebral Veins and Sinuses

Use of Statins and the Subsequent Development of Deep Vein Thrombosis

Anemia of Chronic Disease

Management of Anticoagulation before and after Elective Surgery

Optical probes for detection and quantification of neutrophils’ oxidative burst. A review

Aspirin in the prevention and treatment of venous thromboembolism

Clinical Risk Factors and Timing of Recurrent Venous Thromboembolism During the Initial 3 Months of Anticoagulant Therapy

Estudio multicéntrico, prospectivo, de comparación del tratamiento de la tromboembolia pulmonar submasiva con enoxaparina y heparina no fraccionada

Venous Thromboembolism

Risk Assessment of Recurrence in Patients With Unprovoked Deep Vein Thrombosis or Pulmonary Embolism

Extracellular DNA traps promote thrombosis

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial

The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

Comparative Outcomes of Catheter-Directed Thrombolysis Plus Anticoagulation vs Anticoagulation Alone to Treat Lower-Extremity Proximal Deep Vein Thrombosis

Highly efficient conversion of superoxide to oxygen using hydrophilic carbon clusters

The Risk of Early Recurrent Venous Thromboembolism after Oral Anticoagulant Therapy in Patients with the G20210A Transition in the Prothrombin Gene

Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis

Vena caval filters: a comprehensive review

Clinical iron deficiency disturbs normal human responses to hypoxia

Extended Oral Anticoagulant Therapy after a First Episode of Pulmonary Embolism

Thrombolysis for acute deep vein thrombosis

Incidence of Idiopathic Deep Venous Thrombosis and Secondary Thromboembolism among Ethnic Groups in California

Oral Rivaroxaban for Symptomatic Venous Thromboembolism

The Postthrombotic Syndrome: Evidence-Based Prevention, Diagnosis, and Treatment Strategies

American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy

Duration of anticoagulation following venous thromboembolism: a meta-analysis.

Natural History of Venous Thromboembolism

Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension

Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial

ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease

American Heart Association/American College of Cardiology Foundation guide to warfarin therapy11The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.This statement has been co-published in the April 1, 2003, issue of Circulation.This statement was approved by the American Heart Association Science Advisory and Coordinating Committee in October 2002 and by the American College of Cardiology Board of Trustees in February 2003. A single reprint is available by calling 800-242-8721 (US only) or writing the American Heart Association, Public Information, 7272 Greenville Ave, Dallas, TX 75231-4596. Ask for reprint No. 71-0254. To purchase additional reprints: up to 999 copies, call 800-611-6083 (US only) or fax 413-665-2671; 1000 or more copies, call 410-528-4426, fax 410-528-4264, or e-mail klbradle@lww.com. To make photocopies for personal or educational use, call the Copyright Clearance Center, 978-750-8400.

Low Molecular Weight Heparin versus Acenocoumarol in the Secondary Prophylaxis of Deep Vein Thrombosis

Factor V Leiden Mutation Is a Risk Factor for Cerebral Venous Thrombosis

Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes (II)

Paget-Schroetter syndrome: A review and Algorithm (WASPS-IR)

Factor V Leiden and Risks of Recurrent Idiopathic Venous Thromboembolism

Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis.

Residual Thrombosis on Ultrasonography to Guide the Duration of Anticoagulation in Patients With Deep Venous Thrombosis

Systematic Review: d-Dimer to Predict Recurrent Disease after Stopping Anticoagulant Therapy for Unprovoked Venous Thromboembolism

Clinical Predictors for Fatal Pulmonary Embolism in 15 520 Patients With Venous Thromboembolism

Warfarin therapy: evolving strategies in anticoagulation.

2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation

Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism

Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum

Iron Supplementation in Nephrology and Oncology: What Do We Have in Common?

Detection, evaluation, and management of iron-restricted erythropoiesis

The Epidemiology of Venous Thromboembolism

Extended Prophylaxis of Venous Thromboembolism with Idraparinux

The Risk for Fatal Pulmonary Embolism after Discontinuing Anticoagulant Therapy for Venous Thromboembolism

Low Molecular Weight Heparin (Enoxaparin) Versus Oral Anticoagulant Therapy (Acenocoumarol) in the Long-Term Treatment of Deep Venous Thrombosis in the Elderly: a Randomized Trial

Iron-Deficiency Anemia

The Epidemiology of Venous Thromboembolism in the Community: Implications for Prevention and Management

Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) study

Cerebral venous thrombosis

Management of Deep Vein Thrombosis and Pulmonary Embolism

Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis

Multiple Myeloma

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

Residual Venous Thrombosis as a Predictive Factor of Recurrent Venous Thromboembolism

Generation and Detection of Reactive Oxygen Species in Photocatalysis

Natural History of Thromboembolic Disease After Total Hip Arthroplasty

Predictive Value of D-Dimer Test for Recurrent Venous Thromboembolism After Anticoagulation Withdrawal in Subjects With a Previous Idiopathic Event and in Carriers of Congenital Thrombophilia

Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism

Risk of Venous Thromboembolism Recurrence: High Negative Predictive Value of D-dimer Performed after Oral Anticoagulation Is Stopped

Treatment of erythropoietin deficiency in mice with systemically administered siRNA

Mechanisms for Regulation of Fluid Shear Stress Response in Circulating Leukocytes

The Epidemiology of Venous Thromboembolism in the Community

Systematic Review: Case-Fatality Rates of Recurrent Venous Thromboembolism and Major Bleeding Events Among Patients Treated for Venous Thromboembolism

Comparison of 3 and 6 Months of Oral Anticoagulant Therapy After a First Episode of Proximal Deep Vein Thrombosis or Pulmonary Embolism and Comparison of 6 and 12 Weeks of Therapy After Isolated Calf Deep Vein Thrombosis

Mutation of the gastric hydrogen-potassium ATPase alpha subunit causes iron-deficiency anemia in mice

How I treat isolated distal deep vein thrombosis (IDDVT)

Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis

Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study

Post‐thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months

The importance of the costoclavicular space in upper limb primary deep vein thrombosis, a study with magnetic resonance imaging (MRI) technique enhanced by a blood pool agent

Asymptomatic Deep Venous Thrombosis is Associated with a Low Risk of Post-thrombotic Syndrome

A follow-up study of the fate of small asymptomatic deep venous thromboses

A Comparison of Six Weeks with Six Months of Oral Anticoagulant Therapy after a First Episode of Venous Thromboembolism

Measurement of methemoglobin formation from oxyhemoglobin a real-time, continuous assay of nitric oxide release by human polymorphonuclear leukocytes

The Duration of Oral Anticoagulant Therapy after a Second Episode of Venous Thromboembolism

Hemodynamic and morphologic evaluation of sequelae of primary upper extremity deep venous thromboses treated with anticoagulation

Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders.

Prolonged Thromboprophylaxis With Dalteparin After Surgical Treatment of Achilles Tendon Rupture: A Randomized, Placebo-Controlled Study

A Comparison of Six Weeks With Six Months of Oral Anticoagulant Therapy After a First Episode of Venous Thromboembolism